Brief: Bioxytran Inc Reports Positive Phase 1B/2A Clinical Study Results For Prolectin-M, Broad-Range Antiviral Drug In Mild To Moderate Covid-19
02/03/2026 14:29
March 2 (Reuters) - Bioxytran Inc BIXT.PK: BIOXYTRAN INC: REPORTS POSITIVE PHASE 1B/2A CLINICAL STUDY RESULTS FOR PROLECTIN-M, BROAD-RANGE ANTIVIRAL DRUG IN MILD TO MODERATE COVID-19 BIOXYTRAN INC - NO SERIOUS ADVERSE EVENTS REPORTED, NO TREATMENT-RELATED DISCONTINUATIONS OCCURRED- SEC FILING BIOXYTRAN INC - PROLECTIN-M WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS - SEC FILING Source text: [] Further company coverage: BIXT.PK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bioxytran
See all newsUS officials pressed China on rare earths, farm goods commitments, Bessent says (updated)
Italy's Angelini Pharma completes $4.1 billion state-backed takeover of Catalyst (updated)
Italy's Angelini Pharma completes $4.1 billion state-backed takeover of Catalyst
Brief: Bioxytran Inc Reports Positive Phase 1B/2A Clinical Study Results For Prolectin-M, Broad-Range Antiviral Drug In Mild To Moderate Covid-19
Brief: Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance With Prolectin-Mbioxytran